about
Hemostatic properties of four devices for partial nephrectomy: a comparative ex vivo study.IL1RN and KRT13 Expression in Bladder Cancer: Association with Pathologic Characteristics and Smoking StatusStandardized comparison of prostate morcellators using a new ex-vivo model.Costs of radical prostatectomy for prostate cancer: a systematic review.Cost comparison of robotic, laparoscopic, and open radical prostatectomy for prostate cancer.Intravesical mitomycin C for superficial transitional cell carcinoma.The modern management of upper tract urothelial cancer: surgical treatment.Relaxed imprinting of IGF2 in peripheral blood cells of patients with a history of prostate cancer.Experimental models for therapeutic studies of transitional cell carcinoma.Molecular biomarkers for urothelial carcinoma of the bladder: challenges in clinical use.Interobserver variation in grading and staging of squamous cell carcinoma of the penis in relation to the clinical outcome.The role of lymphangiogenesis in lymphatic tumour spread of urological cancers.Impact of tumor location on prognosis for patients with upper tract urothelial carcinoma managed by radical nephroureterectomy.Prognostic factors of papillary renal cell carcinoma: results from a multi-institutional series after pathological review.Translational research in bladder cancer: from molecular pathogenesis to useful tissue biomarkers.Upper urinary tract urothelial carcinoma with loco-regional nodal metastases: insights from the Upper Tract Urothelial Carcinoma Collaboration.External validation of postoperative nomograms for prediction of all-cause mortality, cancer-specific mortality, and recurrence in patients with urothelial carcinoma of the bladder.Evaluation of the prognostic significance of altered mammalian target of rapamycin pathway biomarkers in upper tract urothelial carcinoma.Oncologic Response and Hospitalization Rate of Patients Receiving Cabazitaxel in the Fourth-Line and Beyond in Castration-Resistant Prostate Cancer: Analysis of a Retrospective Cohort and a Structured Literature Review.Expression of the p53 Inhibitors MDM2 and MDM4 as Outcome Predictor in Muscle-invasive Bladder Cancer.Digital Mapping of the Urinary Bladder: Potential for Standardized Cystoscopy Reports.Assessing the invasive potential of bladder cancer: development and validation of a new preclinical assay.The Use of Neoadjuvant Chemotherapy in Patients With Urothelial Carcinoma of the Bladder: Current Practice Among Clinicians.Postoperative Nomogram for Relapse-Free Survival in Patients with High Grade Upper Tract Urothelial Carcinoma.External validation of a risk model to predict recurrence-free survival after radical cystectomy in patients with pathological tumor stage T3N0 urothelial carcinoma of the bladder.Altered Expression of the Transcription Factor Forkhead Box A1 (FOXA1) Is Associated With Poor Prognosis in Urothelial Carcinoma of the Upper Urinary Tract.Endothelin-A-receptor antagonism with atrasentan exhibits limited activity on the KU-19-19 bladder cancer cell line in a mouse model.Clinical staging error in prostate cancer: localization and relevance of undetected tumour areas.Evaluation of cytotoxic effects induced by bcl-2 and bcl-xL antisense-oligodeoxynucleotides in normal urothelium and transitional cell carcinoma.Topical chemotherapy in human urothelial carcinoma explants: a novel translational tool for preclinical evaluation of experimental intravesical therapies.Evaluation of cystine transport in cultured human kidney cells and establishment of cystinuria type I phenotype by antisense technology.Optimizing chemotherapy for transitional cell carcinoma by application of bcl-2 and bcl-xL antisense oligodeoxynucleotides.Newly developed mini-endoscope for diagnosis and follow-up of orthotopic bladder transitional-cell carcinoma in vivo.Impact of photodynamic diagnosis-assisted transurethral resection of bladder tumors on the prognostic outcome after radical cystectomy: results from PROMETRICS 2011.Prediction of Locally Advanced Urothelial Carcinoma of the Bladder Using Clinical Parameters before Radical Cystectomy--A Prospective Multicenter Study.Prognostic role of ERCC1 protein expression in upper tract urothelial carcinoma following radical nephroureterectomy with curative intent.FOXM1 predicts overall and disease specific survival in muscle-invasive urothelial carcinoma and presents a differential expression between bladder cancer subtypesTALL score for prediction of oncological outcomes after radical nephroureterectomy for high-grade upper tract urothelial carcinoma.The influence of body mass index on the cost of radical prostatectomy for prostate cancer.Lymphovascular invasion is an independent predictor of oncological outcomes in patients with lymph node-negative urothelial bladder cancer treated by radical cystectomy: a multicentre validation trial.
P50
Q33330074-C16391D8-04C6-4241-AD0D-CDCED8D17304Q33992811-36270A24-8FAF-4CE4-B1F6-70E4AC14025BQ34091644-C4B15959-92BD-47EF-9C10-44C1B3DF9659Q34415274-7CBE9966-435C-44E9-B279-7A4F8B62F206Q35014140-7FF40709-8A07-4DFF-AB2A-6FD4D08B6AB0Q36573853-3C45CDE0-2913-4701-A276-5417F4DEC598Q36793128-741D38E4-452C-462A-B44B-FCDC9139027BQ36925646-FA885214-1BFA-4D25-923B-38568A862F1AQ36985572-3B5F10F5-A4C5-48DC-81BA-45028B0E4D90Q37339723-1CC286A6-FBAC-4728-84B8-6FEE36C1BE15Q37394154-BDA3AAB8-CDF1-4B8B-AEA0-2ED24135D14BQ37548744-FE83FA26-01CB-4C59-BF72-FCC58F3015F0Q37556918-7B2A9E5A-D2C4-4427-B4C8-FC2F084F576FQ37652862-0FBF5786-75C5-4A45-A53D-EA0C6E3F93C6Q37777947-06B3B462-B27C-48E9-8778-089239B6CED2Q37844679-3247FBFC-14A5-4C06-BAF2-50DC25F45A1BQ37917241-8BFFABE2-DA04-4F53-A4F4-2C97570FD707Q38274588-0D34FF8E-3AE2-4B10-B842-475C2C00CA41Q38682250-ED129851-7917-4B51-83B8-8FC05D8839B2Q38734842-75D06838-677D-4894-B036-F5DC32A37A63Q38953954-8C2B86AF-54B2-4CFF-9730-34A9FBECA8AEQ39259944-BC31A235-FF76-4150-B501-0DB13B1597DDQ39265374-768F26E5-E45E-428C-9143-44A1F357F8CBQ39349302-111EF8F6-15ED-42A8-8FFD-84F7D143DC13Q39652224-8954C193-2A10-4D38-A9DA-9E15D2013B4FQ39743020-8E29C54F-2E70-4D71-9CDA-82048115B5B9Q39853377-5DEE9561-957D-4D6D-8A9F-F92954C1B10DQ39869978-C819C62B-60E8-426B-8F4B-E48B552D5404Q39914470-BC50B4E7-3F1C-4D3A-A454-65E8602E062DQ39952157-78EEC0B8-9BFF-4988-BD3A-495CAE1BA980Q40036576-D2E96811-C15B-4074-8F4B-39DB227A4EFFQ40042698-24345B2C-FC4F-4F4A-814A-93E3BF6D9DB2Q40092303-325B70BB-1A05-48D5-AE4B-32669794FFCDQ40701908-76B61E4D-9842-4322-90F8-F2DF123459A3Q40772011-71884B8B-6850-4983-857B-CF7D75FF6260Q41056921-2C8B413B-ED00-49D3-95FF-6E8C599A08DFQ41471202-14A7D2CD-CB87-4127-9802-AFE3780654F3Q41750995-10699BF1-144C-4201-9DEE-7067E0280196Q42654270-694051CB-7FB1-4C7E-9747-E97D48F537BBQ43196454-4173D8E9-5A89-41D3-B83B-9A57489B8C62
P50
name
Christian Bolenz
@ast
Christian Bolenz
@en
Christian Bolenz
@nl
type
label
Christian Bolenz
@ast
Christian Bolenz
@en
Christian Bolenz
@nl
prefLabel
Christian Bolenz
@ast
Christian Bolenz
@en
Christian Bolenz
@nl